PTO/SB/08A (08-03)

Approved for use through 07/31/2006, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE aperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

tute for form 1449/PTO

Sheet 1

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 1

Complete if Known

Application Number 10/643,649

Filing Date August 18, 2003

First Named Inventor. CHU, Jack et al.

Art Unit 3763

Examiner Name Unassigned

Attorney Docket Number PA1515

			U. S. PATEN	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (7 known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
TN	AA	<sup>US-</sup> 2003/125800	07/03/2003	Shulze et al.	
TN	AB	<sup>US-</sup> 5,972,027	12/05/2000	Johnson	
TN	AC	<sup>US-</sup> 6,156,062	12/05/2000	McGuinness	
		US-			
	1	US-			
		US-		· · · · · · · · · · · · · · · · · · ·	
		US-	<u> </u>		
		US-		<u> </u>	
		US-			

Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	
			MM-DD-YYYY			Τ°
_TN	AD	WO 98/56312	12/17/1998	Scimed Life		
TN	AE	EP 0761251	03/12/1997	Kabushikikaisha		
					_	L
				- <u></u>	ļ	┡
						L

Examiner Signature	/Timothy Neal/	Date Considered	07/03/2006

\*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

RADENIA!

Sheet 1

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known				
Application Number	10/643,649			
Filing Date	August 18, 2003			
First Named Inventor	Chu et al.			
Art Unit	Unknown	_		
Examiner Name	Unknown			
Attorney Docket Number	PA1515 (MEDT/0018)			

Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	
muais		Number-Kind Code <sup>2 (# known)</sup>	WIM-DU-1111	Applicant of Cited Document	Figures Appear	
TN	1	<sup>ŪS-</sup> 6,348,062	02/19/2002	Incept LLC		
		US-				
		US-				
		US-				
		US-		-		
·····		US-				
<del></del>		US-	<del>-</del>			
		US-			· · · · · · · · · · · · · · · · · · ·	
		US-			<del></del>	
		US-				
		US-				
		US-		1		
		US-				
		US-				
		US-				
		US-				
		US-				
		US-	-			
-		US-				

		FORE	<b>IGN PATENT DOCU</b>	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document			Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Or Relevant Figures Appear	T
						L
				·		┡
· · · · · · · · · · · · · · · · · · ·				<del>" "</del>		┢
						╄

Examiner		Date	
	/m!k\7 /	.	
Signature	/Timothy Neal/	Considered	07/02/0006
	,,		07/03/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>2</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for formation

US-6,531,154

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of |3

Application Number 10/643,649 Filing Date August 18, 2003 First Named Inventor Chu et al. Art Unit Unknown **Examiner Name** Unknown Attorney Docket Number PA1515 (MEDT/0018)

Complete if Known

Sheet 1 **U. S. PATENT DOCUMENTS** Cite No.1 Examine **Document Number Publication Date** Name of Patentee or Pages, Columns, Lines, Where Initials\* MM-DD-YYYY Applicant of Cited Document Relevant Passages or Relevant Number-Kind Code<sup>2</sup> (F known) Figures Appear <sup>US-</sup>2002/0065546 1 05/30/2002 Machan et al. TN SciMed Life Systems, Inc. 2 <sup>US-</sup> 5,538,504 07/23/1996 3 US- 5,670,161 09/23/1997 Healy et al. US- 5.834,449 4 12/10/1998 The Research Foundation of State University of us-New York; Washington University <sup>US-</sup> 6,159,239 5 12/12/2000 Prodesco, Inc. US- 6,190,353 02/20/2001 6 TransVascular, Inc. US-6,302,870 7 10/16/2001 Precision Vascular Systems, Inc. US- 6,344,035 8 02/05/2002 Surmodics, Inc. US- 6,348,050 9 02/19/2002 Medtronic, Inc. 10 US-6,364,903 04/02/2002 Meadox Medicals, Inc. US- 6,368,346 11 04/09/2002 American Medical Systems, Inc. <sup>US-</sup> 6,371,970 12 04/16/2002 Incept LLC US-6,376,742 04/23/2002 Zdrahala et al. 13 US- 6,387,121 05/14/2002 14 Inflow Dynamics Inc. US- 6,451,373 09/17/2002 Advanced Cardiovascular Systems, Inc. 15 Kong Kook Pharmaceutical Co., Ltd. 16 <sup>US-</sup> 6,506,410 01/14/2003 <sup>US-</sup> 6,514,515 17 02/04/2003 Tepha, Inc.

			<b>IGN PATENT DOCU</b>	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>3</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	7
TN	1	WO-02/15824-A2	02/28/2002	Kensey Nash Corporation		
	ļ <u>.</u>					
	ļ					L
	1					

Brown University Research Foundation

03/11/2003

Examiner Signature	/Timothy Neal/	Date Considered	05/02/0006
3.8.2.2.3	, 0 1110 0112 110 112,	Considered	07/03/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

The Paper Work Reduction Act on 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	te for form 14497RFOR				Complete if Kn wn
0003810		MUCKE		Application Number	10/643,649
info	DRMATION	DIS	CLOSURE	Filing Date	August 18, 2003
STATEMENT BY APPLICANT				First Named Inventor	Chu et al.
	/lico ne monu cho	ote se n	ococcand	Art Unit	Unknown
(Use as many sheets as necessary)			ecessary)	Examiner Name	Unknown
Sheet	2	of	3	Attorney Docket Number	PA1515 (MEDT/0018)

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No.1		
TN	1		
	2	"Beta Blockers." <u>Cardiac Consultants.</u> 18 March 2003 <a href="http://www.cardiacconsultants.com/beta.htm">http://www.cardiacconsultants.com/beta.htm</a> .	
	3	"Beta Blockers (Beta-Adrenergic Bockers, Beta 1 Blockers, Beta 2 Blockers, B-Blockers)." <u>HeartCenterOnline</u> , 18 March 2003 <a <="" href="http://www.heartcenteronline.com/myheartdr/common/articles.cfm?ARTID=331&gt;." td=""><td></td></a>	
	4	"beta-blocker." Bartleby.com. 18 March 2003 <a href="http://www.bartleby.com/65/be/beta-b.html">http://www.bartleby.com/65/be/beta-b.html</a> .	
	5	Slaiby, Jeffrey M. et al. "Expansion of aortic aneurysms is reduced by proparanolol in a hypertensive rat model." <u>Journal of Vascular Surgery</u> . 21 January 2002 <a href="http://www.harcourthealth.com/scripts/om.dl/serve?action=searchDB&amp;searchDBfor=art&amp;a&gt;.">http://www.harcourthealth.com/scripts/om.dl/serve?action=searchDB&amp;searchDBfor=art&amp;a&gt;."</a>	
	6	Vine, N. et al. "Metalloproteinases in degenerative aortic disease." Clinical Science 1991, 81: 233-239.	
	7	Goodman, Louis Sanford and Albert Gilman. The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 2001.	
	8	Jackson, Edwin K. "Renin and Angiotensin." 809-835.	
	9	Liao, Shixiong et al. "Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors." <u>Journal of Vascular Surgery</u> . May 2001, 33, No. 5: 1057-1064.	
$\sqrt{}$	10	Chaikof, Elliot L. et al. "Biomaterials and Scaffolds in Reparative Medicine." <u>Annals New York Academy of Sciences</u> 2002, 961: 96-105.	

I Examiner		Date	
	/Timether Maal/	Daic	
Signature	/Timothy Neal/	Considered	07/03/2006
<u> </u>		Considered	07/03/2000

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
persons are required to respond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Complete if Known Substitute for form 1449/ **Application Number** 10/643,649 INFORMATION DISCLOSURE Filing Date August 18, 2003 STATEMENT BY APPLICANT **First Named Inventor** Chu et al. Art Unit Unknown (Use as many sheets as necessary) **Examiner Name** Unknown

Attorney Docket Number

PA1515 (MEDT/0018)

Sheet

3

	T ==	NON PATENT LITERATURE DOCUMENTS	,	
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
TN	11	Griffith, Linda G. "Emerging Design Principles in Biomaterials and Scaffolds or Tissue Engineering." Annals New York Academy of Sciences 2002, 961: 83-95.		
TN	12	Ochoa, Erin R. et al. "An Overview of the Pathology and Approaches to Tissue Engineering."  Annals New York Academy of Sciences 2002, 979: 10-26.		
		·		

Examiner Signature	/Timothy Neal/	Date Considered	07/03/2006	-
-----------------------	----------------	--------------------	------------	---

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.